Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383792 | 0.83 | TGM2 (0.66) | TGM2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL31069810 | 0.83 | TGM2 (0.66) | TGM2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL782552 | 0.81 | TGM2 (1.00) | TGM2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL24168839 | 0.81 | MTNR1B (0.61) | TGM2KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL30539172 | 0.81 | MTNR1B (0.61) | TGM2KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL16053417 | 0.80 | TGM2 (0.64) | TGM2 | |
| SCHEMBL30380385 | 0.79 | TGM2 (0.49) | TGM2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL7826541 | 0.79 | GAA (0.57) | KMT2APOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5509908 | 0.79 | TGM2 (0.56) | TGM2SMN1; SMN2ALDH1A1TP53CYP1A2 | |
| SCHEMBL28102497 | 0.79 | TGM2 (0.56) | TGM2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162039-B | Synthesis method of visible light mediated butanediamide compound | 河南师范大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-116162039-A | Synthesis method of visible light mediated butanediamide compound | 河南师范大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-106008480-A | Quinazoline compound containing cinnamamide structure and preparation method and application thereof | 江西科技师范大学 | 2016-10-12 | — | — | CN | disclosed |
| CN-100497355-C | Hypophosphorous acid derivatives as beta-secretase inhibitors for the treatment of Alzheimer's disease | HOFFMANN LA ROCHE (CH) | 2009-06-10 | — | — | CN | disclosed |
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1878781-A | Hypophosphorous acid derivatives as beta-secretase inhibitors for the treatment of Alzheimer's disease | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| EP-1685142-A1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044830-A1 | PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| US-4302484-A | Polymers crosslinkable by electron beams | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | TGM2 1013/4885KMT2A 2196/4885POLB 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.